ADP's dual income from payroll fees and investing client payroll funds helped it grow steadily over the past decade. A $1,000 investment in ADP in 2016 would be worth $4,147 today with dividends reinvested, outperforming the S&P 500's 243% return. Despite a sharp 2026 slump, ADP's focus on cloud and AI products and a raised fiscal 2027 outlook suggest potential for continued dividend growth. Risks include interest rate cuts and client retention issues, but ADP remains a strong candidate for retirement income portfolios due to its reliable dividend increases.
ADP's steady growth is highlighted by its strong dividend performance over the past decade. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 09, 2026 01:21 WIB: out of 142 priced Financials-sector US stocks tradable on Pluang, 51 rose and 91 fell today. Notable gainers include HUT (Hut 8 Corp) at USD 52.65 with a 1-day change of +14.58%, RIOT (Riot Platforms Inc) at USD 16.71 up +13.21%, and WULF (TeraWulf Inc) at USD 11.37 rising +12.80%.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
Rocket Lab has delayed the debut of its Neutron reusable medium-class rocket to 2027 due to a setback with the first-stage tank. This delay increases the company's reliance on its Electron rocket launches and Space Systems division, putting its path ...
